上皮性卵巢癌病人血清uPA、uPAR和CA125含量检测及其临床意义

目的探讨上皮性卵巢癌病人血清中尿激酶型纤溶酶原激活物（uPA）及其受体（uPAR）和糖蛋白抗原125（CA125）含量的变化及其临床意义。方法采集44例上皮性卵巢癌（卵巢癌组）、35例卵巢良性上皮性肿瘤（良性肿瘤组）和30例正常卵巢（对照组）病人血清标本,用ELISA方法检测血清中uPA、uPAR含量,化学发光法检测血清CA125含量。结果卵巢癌组uPA、uPAR和CA125的分泌水平较良性肿瘤组及对照组明显升高,差异有显著性（F=9.49-4 824.97,q=5.183-119.350,P〈0.01）;良性肿瘤组与对照组各指标比较差异无统计学意义（P〉0.05）。卵巢癌组uPA、uPAR和CA125的分泌水平随着手术病理分期的增高及组织分化程度的降低而增高,差异有显著性（F=15.00~649.46,q=4.467~56.536,P〈0.01）。卵巢癌组有淋巴结和（或）大网膜转移者中uPA和uPAR含量较无转移者明显增高,差异有极显著性（t=8.445-18.608,P〈0.01）。卵巢癌病人血清uPA、uPAR和CA125联合检测的阳性率和敏感度较血清CA125单一检测升高,差异有显著意义（χ2=3.123,P〈0.05）。结论联合检测血清中uPA、uPAR和CA125的含量,对判断卵巢癌的发生发展、浸润和转移有重要意义。

DETECTION OF SERUM uPA,uPAR AND CA125 IN PATIENTS WITH EPITHELIAL OVARIAN CANCER

Objective To explore the clinical significance of the changes of serum levels of urokinase-type plasminegen activator（uPA）,uPA receptor（uPAR） and CA125 in patients with epithelial ovarian cancer（EOC）. Methods Serum samples were collected from 44 patients with EOC,35 with benign ovarian epithelial tumors（BOET） and 30 normal controls.ELISA was used to detect the uPA and uPAR,and biochemical colorimetric method to detect CA125. Results The levels of uPA,uPAR and CA125 in the cancer patients were significantly higher than those of benign and normal controls（F=9.49-4 824.97,q=5.183-119.350,P0.01）.But the differences between benign tumor and normal controls were not statistically significant（P0.05）.The levels of uPA,uPAR and CA125 in the cancer increased with the elevation of pathology staging and degrading of histology differentiation（F=15.00-649.46,q=4.467-56.536,P0.01）,the levels of uPA,uPAR and CA125 were dramatically elevated in those with lymph node and/or omentum metastasis（t=8.445-18.608,P0.01）.The positive rate and sensitivity were higher by combined detection of uPA,uPAR and CA125 than by detection of CA125 alone（χ2=3.123,P0.05）. ConclusionA simultaneous determination of serum levels of uPA,uPAR and CA125 is of great significance in the judgement of the occurrence,development,infiltration and metastasis of ovarian cancer.